PDF
(Download)
|
- African Oil Palm (Elaeis guineenis)
- Mistletoe Fig (Ficus deltoidea)
- Pre-diabetes
|
Date:
05-31-2013 | HC# 051351-473
|
Re: Evaluation of the Effectiveness and Safety of African Oil Palm and Mistletoe Fig Leaf Extracts in Adults with Pre-diabetes
Kalman DS, Schwartz HI, Feldman S, Krieger DR. Efficacy and safety
of Elaeis guineensis and Ficus deltoidea leaf extracts in adults
with pre-diabetes. Nutr J. April 1, 2013;12:36.
doi: 10.1186/1475-2891-12-36.
People
with pre-diabetes have an increased risk of developing diabetes, heart disease,
and stroke. Pre-diabetes is defined as having fasting plasma glucose (FPG) concentrations
of 100-125 mg/dl or 2-hr plasma glucose (PG) values during the oral glucose
tolerance test (OGTT) of 140-199 mg/dl. During 2005-2008 in the United States,
35% of all adults ≥ 20 years of age and 50% of adults ≥ 65 years of age had pre-diabetes.
Other than lifestyle modifications, there are no treatments for pre-diabetes.
African oil palm (Elaeis guineensis)
leaf extract reduced glycemia in rats. Mistletoe fig (Ficus deltoidea) leaf extract enhanced insulin-simulated glucose
uptake in animals. Hence, the purpose of this randomized, double-blind,
parallel-group study was to evaluate the safety and efficacy of African oil
palm and mistletoe fig leaf extracts in adults with pre-diabetes.
Otherwise
healthy adults (n = 30; aged 21-65 years) with pre-diabetes, a body mass index
(BMI) of ≥ 25 kg/m2 and < 40 kg/m2, and a waist
circumference of > 37 inches for men and > 31 inches for women
participated in this study conducted in Miami, Florida. Specific exclusion
criteria were not reported. Patients received either 500 mg of African oil palm
leaf extract (OPLE), 1000 mg of OPLE, or 1000 mg of mistletoe fig leaf extract
for 8 weeks. The treatments were prepared by Biotropics Malaysia Berhad; Selangor, Malaysia. Blood was drawn
at 2, 4, and 8 weeks. Primary efficacy was measured by assessing changes in FPG
and insulin via OGTT; and secondary efficacy was assessed by measuring changes
in body weight and waist circumference.
At
baseline, there were no statistically significant differences between groups.
At 8 weeks, FPG was significantly decreased compared with baseline in the 500
mg OPLE group (P = 0.015); it approached significance in the 1000 mg OPLE group;
and there was no change in the mistletoe fig group. Fasting plasma insulin
values significantly decreased at 4 weeks and 8 weeks compared with baseline in
the 500 mg OPLE group only (P = 0.02 and P = 0.04, respectively). The 500 mg
OPLE group had a significant increase in insulin sensitivity (P = 0.027) and a decrease
in insulin resistance (P = 0.055). The mistletoe fig group had clinically
significant decreases in total and low-density lipoprotein (LDL) cholesterol
concentrations at 8 weeks (P = 0.049 and P = 0.012, respectively). The other
groups had no significant changes in cholesterol. At 8 weeks, there was no
significant change in body weight; even though at 4 weeks, there were increases
in body weight in the 1000 mg OPLE group (P = 0.026) and in the 500 mg OPLE
group (P = 0.080, non-significant). At week 8, waist circumference was significantly
decreased in both the 500 and 1000 mg OPLE groups (P < 0.009 and P < 0.004,
respectively), but not in the mistletoe fig group. Treatment compliance was
93%.
There
were no significant differences in vital signs or lab safety tests. There were
no serious adverse events (AEs). Only 1 of 18 AEs were considered possibly
related to treatment (intermittent light-headedness); the specific treatment
was not indicated. One patient in the 500 mg OPLE group dropped out due to an
AE; however, the event was not described and was not considered possibly or
probably related to treatment.
The
authors conclude that 500 mg of OPLE had a clinically significant beneficial
effect on fasting glucose levels in patients with pre-diabetes. They note that
a larger population size would be needed to overcome the intra-subject
variability that affected the results of the 1000 mg OPLE group. Both OPLE
doses improved waist circumference, which is an important risk factor for
metabolic syndrome. The authors chose not to comment on the mechanism of action
because it was not evaluated in this study. They note that animal studies
indicate that mistletoe fig helps with hyperglycemia; however, this clinical
study did not demonstrate this effect in humans. Additional studies should be
conducted to further evaluate the lipid-lowering effect of mistletoe fig. All 3
treatments were safe and well tolerated. This study is limited by the very
small population size (n = 9-10 patients/group) and the lack of a placebo
control. The findings need to be confirmed with a larger, placebo-controlled
study.
—Heather S. Oliff,
PhD
|